SCHEMBL146157

SCHEMBL146157

O=C(O)c1cccnc1SSc1ncccc1C(=O)O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.62
CYP2C9 P11712 1/20 0.62
KDM4E B2RXH2 2/20 0.61
TDP1 Q9NUW8 1/20 0.61
SMN1; SMN2 Q16637 4/20 0.60
GAA P10253 2/20 0.60
NPC1 O15118 1/20 0.60
RAB9A P51151 1/20 0.60
CYP3A4 P08684 1/20 0.59
MAPT P10636 1/20 0.59
ALOX15 P16050 1/20 0.59
TSHR P16473 1/20 0.59
BLM P54132 1/20 0.59
AGER Q15109 1/20 0.59
NPSR1 Q6W5P4 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
PKM P14618 1/20 0.58
NAPRT Q6XQN6 2/20 0.57
LMNA P02545 1/20 0.57
TP53 P04637 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11504619 0.98 ALDH1A1 (0.60) ALDH1A1CYP2C9KDM4ETDP1SMN1; SMN2
SCHEMBL8371363 0.92 ALDH1A1 (0.58) ALDH1A1CYP2C9KDM4ETDP1SMN1; SMN2
SCHEMBL8370248 0.92 ALDH1A1 (0.58) ALDH1A1CYP2C9KDM4ETDP1SMN1; SMN2
SCHEMBL18798785 0.89 ALDH1A1 (0.55) ALDH1A1CYP2C9KDM4ETDP1SMN1; SMN2
SCHEMBL17153744 0.88 ALDH1A1 (0.55) ALDH1A1CYP2C9KDM4ETDP1SMN1; SMN2
SCHEMBL5590925 0.84 ALDH1A1 (0.58) ALDH1A1CYP2C9KDM4ETDP1SMN1; SMN2
SCHEMBL10491778 0.84 ALDH1A1 (0.58) ALDH1A1CYP2C9KDM4ETDP1SMN1; SMN2
SCHEMBL355357 0.84 ALDH1A1 (0.59) ALDH1A1CYP2C9KDM4ETDP1SMN1; SMN2
Hydrochloric Acid SCHEMBL1375604 0.82 ALDH1A1 (0.62) ALDH1A1CYP2C9KDM4ETDP1SMN1; SMN2
SCHEMBL21326417 0.82 SMN1; SMN2 (0.55) ALDH1A1CYP2C9KDM4ETDP1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115084518-B Negative electrode binder and application thereof 清华大学深圳国际研究生院 2024-11-01 CN claimed
CN-115084518-A Negative electrode binder and application thereof 清华大学深圳国际研究生院 2022-09-20 CN claimed
CN-114409895-A Semi-aromatic polyamide and preparation method and application thereof 重庆沃特智成新材料科技有限公司 2022-04-29 CN claimed
EP-3965657-A1 MEDIATION OF IN VIVO ANALYTE SIGNAL DEGRADATION Senseonics, Incorporated (US) 2022-03-16 EP claimed
WO-2003099852-A2 PEPTIDE DERIVATIZATION PROCESS RESTORAGEN INC. (US) 2003-12-04 WO claimed
EP-1280866-A1 ACTIVATOR COMPOSITIONS FOR CYANOACRYLATE ADHESIVES Loctite (R & D) Limited (IE) 2003-02-05 EP claimed
WO-2001085861-A1 ACTIVATOR COMPOSITIONS FOR CYANOACRYLATE ADHESIVES LOCTITE (R & D) LIMITED (IE) 2001-11-15 WO claimed
US-4378364-A DITHIOBIS(PYRIDINE-CARBOXYLIC ACID) TO RELIEVE PAIN, INCREASE APPETITE GRASSETTI DAVIDE R 1983-03-29 US claimed
US-4152439-A 6,6-DITHIODINICOTINIC ACID, ESTER OR ALKALI METAL OR AMMONIUM SALT Grassetti, Davide R. (US) 1979-05-01 US claimed
EP-4577189-A1 MUCOADHESIVE PHARMACEUTICAL DOSAGE FORM FOR UNIDIRECTIONAL RELEASE OF PEPTIDE THERAPEUTIC PARTICLES The University of British Columbia (CA) 2025-07-02 EP disclosed
US-20240173262-A1 MUCOADHESIVE PHARMACEUTICAL DOSAGE FORM FOR UNIDIRECTIONAL RELEASE OF PEPTIDE THERAPEUTIC PARTICLES THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2024-05-30 US disclosed
WO-2024040356-A1 MUCOADHESIVE PHARMACEUTICAL DOSAGE FORM FOR UNIDIRECTIONAL RELEASE OF PEPTIDE THERAPEUTIC PARTICLES THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2024-02-29 WO disclosed
WO-2024040356-A1 MUCOADHESIVE PHARMACEUTICAL DOSAGE FORM FOR UNIDIRECTIONAL RELEASE OF PEPTIDE THERAPEUTIC PARTICLES THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2024-02-29 WO disclosed
US-11680946-B1 Detection of cholinesterase inhibition with microfluidic devices and systems thereof NATIONAL TECHNOLOGY & ENGINEERING SOLUTIONS OF SANDIA, LLC (US) 2023-06-20 US disclosed
US-5266560-A Glucose tolerance factor THOMAS RESEARCH CORPORATION (US) 1993-11-30 US disclosed
EP-0552376-A1 PRODUCTION OF POLYMER HYDROXYLATED AT BOTH TERMINALS, COMPOSITION CONTAINING SAID POLYMER AND ITS USE, AND POLYMER DERIVED FROM SAID COMPOSITION AND ITS USE NIPPON SHOKUBAI CO., LTD. (JP) 1993-07-28 EP disclosed
US-4957640-A Corrosion prevention with compositions prepared from organic fatty amines and nitrogen-containing aromatic heterocyclic compounds THE DOW CHEMICAL COMPANY (US) 1990-09-18 US disclosed
US-4765839-A PAVING THE DOW CHEMICAL COMPANY (US) 1988-08-23 US disclosed
US-4761473-A CORROSION RESISTANCE OF OIL OR GAS WELLS THE DOW CHEMICAL COMPANY (US) 1988-08-02 US disclosed
US-4152439-A 6,6-DITHIODINICOTINIC ACID, ESTER OR ALKALI METAL OR AMMONIUM SALT Grassetti, Davide R. (US) 1979-05-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240173262-A1 MUCOADHESIVE PHARMACEUTICAL DOSAGE FORM FOR UNIDIRECTIONAL RELEASE OF PEPTIDE THERAPEUTIC PARTICLES GLP1R, IAPP, GIPR ALDH1A1 4462/4885CYP2C9 2287/4885KDM4E 4582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.